• The impact of immune checkpoint inhibitors on cost and quality of life in the initial treatment of patients with advanced or metastatic NSCLC.
  Procailo Kelly et al. The American journal of managed care 2021 27(18 Suppl) S333-S339
• Deep Mining Generation of Lung Cancer Malignancy Models from Chest X-ray Images.
  Horry Michael et al. Sensors (Basel, Switzerland) 2021 21(19)
• Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.
  Tu Hai-Yan et al. Clinical lung cancer 2021
• Single-cell RNA sequencing for the identification of early-stage lung cancer biomarkers from circulating blood
  J Kim et al, NPJ Genomic Medicine, October 15, 2021
• Comprehensive Analysis of TP53 and KEAP1 Mutations and their Impact on Survival in Localized and Advanced Stage Non-Small Cell Lung Cancer.
  Saleh Mohamed Mahde et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2021
• Interactive Machine Learning-Based Multi-Label Segmentation of Solid Tumors and Organs.
  Bounias Dimitrios et al. Applied sciences (Basel, Switzerland) 2021 11(16)
• Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach.
  Heilbroner Samuel Peter et al. Journal for immunotherapy of cancer 2021 9(10)
• Liquid Biopsy from research to clinical practice: focus on Non-Small Cell Lung Cancer.
  Malapelle Umberto et al. Expert review of molecular diagnostics 2021
• The Genomics of Young Lung Cancer: Comprehensive Tissue Genomic Analysis in Patients Under 40 With Lung Cancer.
  Gitlitz Barbara J et al. JTO clinical and research reports 2021 2(7) 100194
• Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer.
  Zhao Shen et al. BMC medicine 2021 19(1) 223

More